stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Return on assets
Ionis Pharmaceuticals, Inc.'s return on assets over the twelve months to 30 June 2026 was −18.9%, down 7.2 percentage points from fiscal 2025 (−11.7%). Over the past ten years it has ranged from −15.8% (fiscal 2020) to 13.7% (fiscal 2018); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −11.7% | 3.46 |
| FY2024 | −15.2% | (1.89) |
| FY2023 | −13.3% | (2.78) |
| FY2022 | −10.5% | (9.34) |
| FY2021 | −1.14% | 14.66 |
| FY2020 | −15.8% | (25.23) |
| FY2019 | 9.43% | (4.29) |
| FY2018 | 13.7% | 13.69 |
| FY2017 | 0.03% | 6.52 |
| FY2016 | −6.49% | 2.78 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 2.77% |
| ORKA Oruka Therapeutics, Inc. compare | −17.8% |
| IONS Ionis Pharmaceuticals, Inc. | −18.9% |
| AXSM Axsome Therapeutics, Inc. compare | −21.0% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −21.6% |
| CGON CG Oncology, Inc. compare | −25.1% |
| IMVT Immunovant, Inc. compare | −71.1% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −99.8% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement